Félicitations à l’Equipe MRS Lauréate de la “FRM équipe” 2025

In silico design of new Kv7.2 channel activators coupled with genetherapy: New horizons for effectively treating spasticity

Spasticity, characterized by muscle hypertonia, affects over 12 million people. Current therapies offer limited relief. Building on our work showing that Kv7.2 channels limit motoneuron excitability by opposing persistent sodium current, we found that their dysfunction after spinal cord injury contributes to spasticity. 

Targeting Kv7.2 channels, using computational drug design and gene therapy, our project aims to develop safe, effective treatments, validated in our unique mouse models, with the potential to transform patient care.